Ultime notizie per Prenetics Global (NASDAQ:PRE) Azioni

PartnerRe

PartnerRe Ltd.

NYSE

Prenetics Global

Prenetics Global Ltd is a health sciences company dedicated to consumer and clinical health. Its consumer initiative is led by IM8, a new health and wellness brand, and Europa, a U.S. sports distribution company. The clinical division is led by Insighta, focused on multi-cancer early detection technologies. This is followed by ACT Genomics, which has achieved FDA clearance for genomic profiling of solid tumors, and CircleDNA, which uses NGS to offer DNA tests. Each Prenetics unit impacts health by 'enhancing life through science'.

Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>), a leading consumer health sciences company, announced today at a special event at Wimbledon House that IM8, its premium supplements brand co-founded by David Beckham, has partnered with world No. 1 tennis star Aryna Sabalenka as its newest global ambassador and shareholder. The announcement comes just days before the start of Wimbledon on June 30th, where Sabalenka will be competing as one of the tournament favorites.
 &nbsp;
The partnership marks a significant milestone for both Sabalenka and IM8, as this represents the first time the tennis champion has endorsed a supplement brand. The collaboration was born organically after Sabalenka experienced remarkable benefits from using IM8's Daily Ultimate Essentials, which is NSF Certified for Sport&#xAE;, since the beginning of 2025.
Sabalenka, who is preparing for Wimbledon after an impressive first half of 2025 that saw her claim three prestigious titles in Brisbane, Miami, and Madrid, has reported significant improvements in energy, endurance, digestion, and cognitive focus since incorporating IM8 into her daily routine. Her entire team, including her tennis coaches and personal trainer, have also become regular users of the product.

News

Prenetics Global Teams Up with Aryna Sabalenka as IM8 Brand Ambassador and Shareholder

Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) announced on Wednesday that it had completed a $20 million in Bitcoin (CRYPTO: BTC/USD) purchase of 187.42 BTC at an average price of $106,712 <a target="_blank" href="https://www.benzinga.com/topic/bitcoin" rel="noreferrer noopener">per Bitcoin</a> via a Kraken custody account.
The move follows divestitures that strengthened Prenetics&#8217; pro-forma cash to approximately $66 million and Pro-forma cash, BTC and short-term assets to roughly $117 million.
The comprehensive long-term Bitcoin strategy, approved by its Board of Directors, includes board approval to allocate most of the company&#8217;s balance sheet to Bitcoin, implement an alpha-generating strategy, and institutional discussions for expanded Bitcoin acquisition.
Also Read: <a target="_blank" href="https://www.benzinga.com/markets/cryptocurrency/25/04/44809791/exclusive-janover-scoops-10-5-million-of-solana-under-new-treasury-strategy" rel="noreferrer noopener">Janover Scoops $10.5 Million Of Solana Under New Treasury Strategy</a>
Prenetics plans to increase its Bitcoin holdings substantially and aims to become one of the largest healthcare corporate Bitcoin holders globally.
Prenetics also announced the appointment of Andy Cheung, former COO of OKEx, to its Board of Directors. Mr. Cheung, former COO of OKEx (now one of the world&#8217;s top-3 cryptocurrency exchanges) and current Co-Founder &amp; CEO of both OEX and PredicXion, brings a decade of crypto exchange operations expertise, managing billions in daily trading volume.
Prenetics&#8217; Bitcoin initiative extends far beyond a simple treasury allocation. It represents a comprehensive long-term digital asset strategy directly inspired by successful corporate Bitcoin adopters like MicroStrategy and Metaplanet, who have demonstrated Bitcoin&#8217;s transformative potential as a superior treasury asset.
The Board has approved allocating most of Prenetics&#8217; balance sheet to Bitcoin. The company is actively discussing with leading financial institutions to develop a comprehensive long-term Bitcoin acquisition plan.
The company said it will implement sophisticated alpha-generating strategies, including yield generation, strategic collateralization, and structured products, to maximize returns on its Bitcoin holdings.
Prenetics will soon accept cryptocurrency payments across both of its direct-to-consumer platforms, including IM8 Health and CircleDNA, creating a Bitcoin ecosystem from treasury to operations.
The company said it views Bitcoin not as a speculative investment but as a fundamental transformation of corporate treasury management for the digital age.
Price Action: PRE stock closed higher by 7.13% at $7.51 on Tuesday.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/03/44194807/coinbase-analyst-sees-crypto-spring-ahead-calls-recent-pullback-a-buying-opportunity" target="_blank" rel="noreferrer noopener">Coinbase Is the &#8216;Blue Chip&#8217; Of Crypto, Analyst Likes It On Pullback</a></li>
</ul>
Photo by Paopano via Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Prenetics Acquires $20 Million In Bitcoin To Boost Healthcare Bitcoin Treasury Strategy

-&nbsp; Prenetics adopts proven corporate Bitcoin strategy inspired by MicroStrategy's ~$40B Bitcoin holdings and Metaplanet's meteoric treasury transformation
-&nbsp; Following strategic divestiture, Prenetics leverages strengthened $117M balance sheet to execute comprehensive Bitcoin strategy with board-approved majority allocation, institutional financing partnerships, and alpha-generating initiatives. &nbsp;
CHARLOTTE, N.C., June 18, 2025 (GLOBE NEWSWIRE) -- Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>), a leading health sciences company, today announced it has become the first healthcare company to establish a Bitcoin treasury, completing a $20 million Bitcoin purchase of 187.42 BTC at an average price of $106,712 per Bitcoin via a Kraken custody account.
Concurrent with this groundbreaking treasury strategy, Prenetics announced the appointment of Andy Cheung, former COO of OKEx, to its Board of Directors, providing direct board-level oversight from one of the crypto industry's most experienced executives. Prenetics plans to substantially increase its Bitcoin holdings and aims to become one of the largest healthcare corporate Bitcoin holders globally.

Prenetics Global Secures $20M In BTC And Announces Pro-Forma Cash Strengthened To ~$66M With BTC And Short-Term Assets $117M

Prenetics Global Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) ("Prenetics"), a leading consumer health sciences company, today announced it has entered into a definitive agreement to divest its ownership in ACT Genomics Holdings Company Limited ("ACT Genomics") to Delta Electronics, Inc. (TWSE: 2308) ("Delta"). Delta is a global leader in power management and smart green solutions, as well as a provider of healthcare technologies. The transaction regarding Delta's acquisition of up to 100% ACT Genomics' shareholdings is valued at up to US$71.78 million. Prenetics, holding a majority stake in ACT Genomics, will receive a gross proceed of approximately US$46 million in cash post-closing of the transaction and subject to customary release conditions. With a cash balance of US$44 million1, this divestment bolsters Prenetics financial position, increasing its pro-forma cash reserves to approximately US$86 million2 and with $117 million pro-forma short term assets3, while maintaining a debt-free balance sheet.
ACT Genomics' expertise in clinical diagnostics and next-generation sequencing (NGS) is expected to complement Delta's existing healthcare solutions portfolio, fostering new synergies and growth opportunities in the precision medicine market.
Danny Yeung, CEO and Co-Founder of Prenetics, commented, "This transaction is a testament to the value we have built within ACT Genomics and marks an important milestone for Prenetics. We are incredibly proud of the ACT Genomics team and their contributions. We are confident that under Delta's stewardship, ACT Genomics will continue to thrive and make significant contributions to the field of genomic medicine."
Strategic Transformation: Simplified Business Model with Exceptional Growth
The divestment of ACT Genomics marks the successful completion of Prenetics' strategic transformation, addressing previous investor feedback regarding business complexity while positioning the company for accelerated growth in the high-margin consumer health market. The transaction enables Prenetics to simplify its investment thesis, enhance financial flexibility, accelerate growth focus, and optimize resource allocation.
Exceptional Consumer Health Performance Validates Strategy: Prenetics' consumer health business has demonstrated remarkable momentum with:
<ul>
<li>Q1 2025 revenue of $14.4 million representing a 336.5% increase year-over-year &nbsp;</li>
<li>Management increased full-year 2025 revenue guidance to US$80-100 million (excluding ACT Genomics), up from the previous range of US$73-85 million, demonstrating confidence in the core business trajectory. &nbsp;</li>
</ul>
IM8 Health Success Story: The flagship IM8 brand, has achieved extraordinary success in just six months since launch with:
<ul>
<li>Over 55,000 customers acquired, 4.9 million servings delivered &nbsp;</li>
<li>Industry-leading 91% subscription rate, US$109 average order value, &nbsp;</li>
<li>Global expansion to 31 countries &nbsp;</li>
<li>Q1 revenue of US$5.7 million and projected Q2 revenue of US$8.5 million (50% quarter-over-quarter growth). &nbsp;</li>
</ul>
Focused Portfolio of Leading Consumer Health Brands: Post-divestment, Prenetics operates three complementary consumer health brands: IM8 (premium health supplements brand), CircleDNA (leading direct-to-consumer DNA testing platform), and Europa (one of the largest sports nutrition distribution companies in the United States).
Enhanced Financial Position Enables Significant Opportunities for Shareholder Value
The ACT Genomics divestment significantly strengthens Prenetics' financial foundation with pro-forma cash reserves of approximately US$86 million and pro-forma cash and short−term assets of US$117 million. The company maintains its debt-free balance sheet with zero debt.
Strategic Investment Portfolio: Beyond its operating businesses, Prenetics maintains a valuable 35% stake in Insighta, an early cancer detection company. Based on Tencent's recent investment in Insighta, this stake is valued at $70 million, representing significant additional value for Prenetics shareholders.
Innovation Leadership: With a robust cash position and accelerating business fundamentals, Prenetics is strategically positioned to explore cutting-edge treasury management approaches, including digital asset adoption and Bitcoin treasury strategies.

Asset Sales

Scholar Rock Unloads Genomics Unit for $46M, Boosting Cash Reserves and Refocusing on Consumer Health Growth

<h3>Gainers</h3>
<ul>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares moved upwards by 17.8% to $9.45 during Friday's pre-market session. The market value of their outstanding shares is at $115.4 million. The company's, Q1 earnings came out yesterday. </li>
<li>Astria Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATXS#NASDAQ">ATXS</a>) shares moved upwards by 13.39% to $6.35. The market value of their outstanding shares is at $358.3 million. </li>
<li>Privia Health Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRVA#NASDAQ">PRVA</a>) stock increased by 12.29% to $25.49. The market value of their outstanding shares is at $3.1 billion. </li>
<li>China Pharma Holding (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) stock moved upwards by 8.8% to $1.73. The market value of their outstanding shares is at $5.6 million. </li>
<li>Wellgistics Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WGRX#NASDAQ">WGRX</a>) stock moved upwards by 7.09% to $1.51. The company's market cap stands at $108.5 million. </li>
<li>Tiziana Life Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLSA#NASDAQ">TLSA</a>) stock rose 7.04% to $1.52. The market value of their outstanding shares is at $177.6 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) stock decreased by 18.8% to $1.6 during Friday's pre-market session. The market value of their outstanding shares is at $35.4 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares decreased by 18.22% to $16.61. The company's market cap stands at $432.1 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares decreased by 17.22% to $0.25. The company's market cap stands at $6.8 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares decreased by 15.67% to $0.03. The company's market cap stands at $10.3 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares fell 13.96% to $0.37. The market value of their outstanding shares is at $4.0 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) stock decreased by 12.11% to $0.13. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ATXS

BIAF

CPHI

HCTI

LIMN

NCNA

PRVA

RNTX

TLSA

VTAK

WGRX

12 Health Care Stocks Moving In Friday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock rose 8.5% to $1.15 during Thursday's after-market session. The company's market cap stands at $6.1 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) stock rose 7.1% to $8.59. The market value of their outstanding shares is at $104.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 7.07% to $0.26. The company's market cap stands at $69.7 million. </li>
<li>Scilex Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCLX#NASDAQ">SCLX</a>) stock moved upwards by 6.58% to $5.5. The market value of their outstanding shares is at $30.2 million. </li>
<li>Nuwellis (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUWE#NASDAQ">NUWE</a>) shares rose 5.91% to $0.33. The company's market cap stands at $1.4 million. </li>
<li>Health Catalyst (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCAT#NASDAQ">HCAT</a>) stock increased by 5.52% to $4.2. The company's market cap stands at $292.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) stock fell 16.3% to $0.03 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Rein Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNTX#NASDAQ">RNTX</a>) shares declined by 12.7% to $1.72. The market value of their outstanding shares is at $38.1 million. </li>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares decreased by 10.79% to $18.12. The company's market cap stands at $471.3 million. </li>
<li>bioAffinity Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIAF#NASDAQ">BIAF</a>) shares declined by 8.63% to $0.28. The market value of their outstanding shares is at $7.5 million. </li>
<li>Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) stock decreased by 8.19% to $4.15. The market value of their outstanding shares is at $388.2 million. </li>
<li>NuCana (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCNA#NASDAQ">NCNA</a>) shares decreased by 6.52% to $0.14. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ADAP

CMPS

HCAT

NUWE

PLRZ

SCLX

12 Health Care Stocks Moving In Thursday's After-Market Session

Leveraging our strong cash position and robust business fundamentals, management is actively advancing our innovative treasury management approach by evaluating strategic crypto initiatives and Bitcoin adoption. We are in active discussions with leading crypto industry veterans and thought leaders to provide expert guidance on digital asset opportunities, which will significantly enhance our crypto strategy decision-making capabilities and strengthen our market positioning in the evolving digital asset space. This forward-thinking approach to corporate finance aims to optimize capital allocation and drive long-term shareholder value creation.

Markets

Prenetics Advances Treasury Strategy With Strategic Crypto Initiatives And Bitcoin Adoption Discussions

Outlook The Company is increasing full-year 2025 revenue guidance to $80 to $100 million from the previously projected $73 to 85 million.
As IM8 continues to demonstrate exceptional growth, and with Q1 2025 revenue of $5.7 million, we expect IM8's second quarter revenue to reach approximately $8.5 million, representing growth of 50% quarter-over-quarter.

Guidance

Prenetics Increases FY25 Revenue Guidance From The Previously Projected $73M-$85M To $80M-$100M

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.80) per share which missed the analyst consensus estimate of $(0.64) by 25 percent. This is a 14.29 percent decrease over losses of $(0.70) per share from the same period last year. The company reported quarterly sales of $17.31 million which beat the analyst consensus estimate of $15.20 million by 13.89 percent. This is a 169.93 percent increase over sales of $6.41 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Prenetics Global Q1 EPS $(0.80) Misses $(0.64) Estimate, Sales $17.31M Beat $15.20M Estimate

<h3>Gainers</h3>
<ul>
<li>SCWorx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WORX#NASDAQ">WORX</a>) shares moved upwards by 71.9% to $0.7 during Friday's after-market session. The company's market cap stands at $1.6 million. </li>
<li>Klotho Neurosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KLTO#NASDAQ">KLTO</a>) stock moved upwards by 24.8% to $0.24. The company's market cap stands at $7.7 million. </li>
<li>Imunon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMNN#NASDAQ">IMNN</a>) shares rose 7.75% to $1.25. The company's market cap stands at $18.2 million. </li>
<li>Tourmaline Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRML#NASDAQ">TRML</a>) stock increased by 6.59% to $16.33. The market value of their outstanding shares is at $419.4 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares moved upwards by 6.45% to $10.98. The market value of their outstanding shares is at $134.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) shares increased by 6.17% to $2.58. The market value of their outstanding shares is at $2.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Prothena Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTA#NASDAQ">PRTA</a>) shares decreased by 23.6% to $5.03 during Friday's after-market session. The market value of their outstanding shares is at $270.7 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) shares decreased by 10.38% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Meihua Intl Medical Techs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MHUA#NASDAQ">MHUA</a>) shares declined by 7.86% to $0.36. The market value of their outstanding shares is at $9.1 million. </li>
<li>SINTX Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SINT#NASDAQ">SINT</a>) shares decreased by 6.82% to $2.6. The market value of their outstanding shares is at $6.5 million. </li>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock decreased by 5.53% to $1.71. The market value of their outstanding shares is at $2.5 million. </li>
<li>Royalty Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RPRX#NASDAQ">RPRX</a>) shares fell 5.03% to $30.82. The company's market cap stands at $12.9 billion. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

IMNN

KLTO

MHUA

PRTA

REVB

RPRX

SINT

TRML

WORX

12 Health Care Stocks Moving In Friday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Vigil Neuroscience (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIGL#NASDAQ">VIGL</a>) shares moved upwards by 241.8% to $7.89 during Thursday's regular session. The company's market cap stands at $368.4 million. </li>
<li>Instil Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIL#NASDAQ">TIL</a>) stock increased by 48.15% to $24.03. The market value of their outstanding shares is at $157.6 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) stock rose 32.85% to $1.86. The company's market cap stands at $5.3 million. As per the news, the Q1 earnings report came out 3 days ago. </li>
<li>Longevity Health Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XAGE#NASDAQ">XAGE</a>) stock rose 27.77% to $3.91. The market value of their outstanding shares is at $3.9 million. </li>
<li>Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) shares increased by 22.86% to $9.94. The company's market cap stands at $121.4 million. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) stock rose 21.24% to $1.85. The market value of their outstanding shares is at $132.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CEL-SCI (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CVM#AMEX">CVM</a>) stock fell 45.5% to $2.46 during Thursday's regular session. The company's market cap stands at $7.4 million. </li>
<li>Basel Medical Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMGL#NASDAQ">BMGL</a>) shares fell 31.29% to $1.28. The market value of their outstanding shares is at $24.1 million. </li>
<li>Catheter Precision (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VTAK#AMEX">VTAK</a>) stock fell 30.47% to $0.21. The company's market cap stands at $2.3 million. </li>
<li>Polyrizon (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRZ#NASDAQ">PLRZ</a>) stock declined by 21.32% to $0.0. </li>
<li>Aptevo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APVO#NASDAQ">APVO</a>) stock fell 21.04% to $0.3. The market value of their outstanding shares is at $2.3 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares declined by 15.01% to $0.01. As per the press release, Q1 earnings came out 2 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

APVO

BMGL

EYEN

VIGL

VTYX

Longevity Health Holdings, Inc. - Common Stock

XAGE

12 Health Care Stocks Moving In Thursday's Intraday Session

For the first quarter of 2025, we expect consumer results to be:
<ul>
<li>Revenue of $11.5 million to $13 million
<ul>
<li>IM8: $4.0 million to $4.5 million</li>
<li>Europa: $5.0 million to $5.5 million</li>
<li>CircleDNA: $2.5 million to $3.0 million</li>
</ul>
</li>
<li>Adjusted EBITDA loss: $(5.5) million to $(6.0) million</li>
</ul>
For the full year 2025, we expect consumer results to be:
<ul>
<li>Revenue of $73 million to $85 million
<ul>
<li>IM8: $30 million to $35 million</li>
<li>Europa: $30 million to $35 million</li>
<li>CircleDNA: $13 million to $15 million</li>
</ul>
</li>
<li>Adjusted EBITDA loss: $(13) million to $(15) million</li>
<li>Q4 2025: Adjusted EBITDA profitable</li>
</ul>

Prenetics Sees Q1 Revenue $11.5M-$13M Vs $11.2M Est.; FY25 Revenue $73M-$85M Vs $75.4M Est.

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly sales of $10.500 million which missed the analyst consensus estimate of $12.400 million by 15.32 percent. This is a 93.43 percent increase over sales of $5.428 million the same period last year.

Prenetics Global Q4 Sales $10.500M Miss $12.400M Estimate

<ul>
<li>CircleDNA powers blockchain-based identity verification with Humanity Protocol, valued at US $1.1bn after latest fundraise</li>
<li>Prenetics invests $1.5M in Bitcoin, Solana and H tokens, supported by strong balance sheet</li>
<li>Prenetics advances Decentralized Science (DeSci) with AI-driven early cancer detection, backed by $30M investment from Tencent</li>
</ul>

Prenetics Partners With Humanity Protocol And Launches Crypto Strategic Reserve; Prenetics Invests $1.5M In Bitcoin, Solana And H Tokens

Cantor Fitzgerald analyst Ross Osborn reiterates Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) with a Overweight and maintains $9 price target.

Price Target

Reiteration

Analyst Ratings

Cantor Fitzgerald Reiterates Overweight on Prenetics Global, Maintains $9 Price Target

Collaboration to Focus on Nutrition, Cellular Rejuvenation, Protein, Collagen and Overall Wellness
IM8, a New Premium Supplements Brand, Launched Officially on November 18th on <a href="https://www.globenewswire.com/Tracker?data=91rCEEadc0RFBygsq67dhEX6Z46j795crsPTx5gKFdBflK5_xqn18v7qVbxs43xMs60CoK0igxLWo80JDhtvNg==">IM8health.com</a>
CHARLOTTE, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Prenetics' (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) IM8, a premium supplements brand focused on science-driven health solutions, is excited to announce a collaboration through a know-how agreement with Mayo Clinic to develop a new generation of premium supplements. This collaboration aims to advance health and longevity through the fusion of IM8's cutting-edge innovation and Mayo Clinic's medical expertise.
The collaboration will focus on creating evidence-based, clinically researched supplements designed to address key health priorities such as optimal nutrition, cellular rejuvenation, protein support, collagen health, muscle recovery, and overall well-being. The work seeks to ensure that every product developed meets the highest standards of science and efficacy, empowering individuals to take charge of their health with confidence.

Biotech

General

Prenetics' IM8 Announces Collaboration With Mayo Clinic To Develop New Line Of Premium Supplements To Focus On Nutrition, Cellular Rejuvenation, Protein, Collagen And Overall Wellness

Mission Aims To Enhance Healthspan On Earth And Astronaut Health In Space, Leveraging Microgravity For Cellular Research And Autophagy Insights

Prenetics' IM8 And University Of Oxford Launch Space Experiment On ISS To Study Accelerated Aging And Longevity

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported its Q3 earnings results on Wednesday, November 27, 2024 at 08:30 AM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Prenetics Global beat estimated earnings by 2.0%, reporting an EPS of $-0.84 versus an estimate of $-0.86.
Revenue was up $2.91 million from the same period last year.
<h3>Historical Earnings Summary</h3>
In the previous quarter, the company beat on EPS by $0.05, resulting in a 9.0% drop change in the share price the following day.

To track all earnings releases for Prenetics Global <a href="https://www.benzinga.com/quote/PRE/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Prenetics Global: Q3 Earnings Insights

Prenetics Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRE#NASDAQ">PRE</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent. This is a 4.55 percent increase over losses of $(0.88) per share from the same period last year. The company reported $7.78 million in sales this quarter. This is a 30.91 percent increase over sales of $5.94 million the same period last year.

Prenetics Global Q3 EPS $(0.84) Beats $(0.86) Estimate, Sales $7.78M Up From $5.94M YoY

Press Releases

Prenetics Unveils IM8 to U.S. Consumers with Co-Founding Partner David Beckham

Nasdaq-Listed Prenetics Announces Genomics-Based Partnership with Humanity Protocol and Launches Crypto Strategic Reserve

Prenetics Announces Fourth Quarter and Full Year 2024 Financial Results, Provides 2025 Guidance

Prenetics to Participate in the 37th Annual ROTH Conference

Management

Prenetics' IM8 Health Expands Scientific Advisory Board, Reinforcing Commitment to Set New Standards in Supplements Market

IM8 Vibrante Miami: Fueling Wellness and Innovation with a Star-Studded Event

Prenetics Announces First Quarter 2025 Financial Results, Raises FY2025 Outlook, & Crypto Strategy Announcement Soon

Contracts

Prenetics Divests ACT Genomics to Delta Electronics as Part of up to US$71.78 Million Transaction

Prenetics Becomes First Healthcare Company to Execute Aggressive Bitcoin Treasury Strategy, Secures $20M in BTC, Appoints Former OKEx COO to Board

World No. 1 Tennis Star Aryna Sabalenka Joins Prenetics' IM8 Health as Global Ambassador and Shareholder

Prenetics Global Limited - Class A Ordinary Share

Comments

Prenetics Global

Notizie

Ultime notizie per Prenetics Global (NASDAQ:PRE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO